Put Options

14 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$39.66 - $51.75 $2.09 Million - $2.73 Million
52,700 New
52,700 $2.73 Million
Q1 2024

May 13, 2024

SELL
$47.98 - $54.4 $335,860 - $380,800
-7,000 Reduced 20.96%
26,400 $1.43 Million
Q4 2023

Feb 14, 2024

BUY
$48.48 - $57.85 $489,647 - $584,285
10,100 Added 43.35%
33,400 $1.71 Million
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $966,763 - $1.08 Million
-16,700 Reduced 41.75%
23,300 $1.35 Million
Q1 2023

May 15, 2023

SELL
$65.71 - $74.53 $8.44 Million - $9.57 Million
-128,400 Reduced 76.25%
40,000 $2.77 Million
Q4 2022

Feb 14, 2023

SELL
$68.48 - $81.09 $22.6 Million - $26.8 Million
-330,000 Reduced 66.21%
168,400 $12.1 Million
Q3 2022

Nov 14, 2022

SELL
$0.13 - $76.84 $37,349 - $22.1 Million
-287,300 Reduced 36.57%
498,400 $35.4 Million
Q2 2022

Aug 15, 2022

BUY
$72.62 - $79.98 $777,034 - $855,786
10,700 Added 1.38%
785,700 $60.5 Million
Q1 2022

May 16, 2022

BUY
$61.48 - $73.72 $46.9 Million - $56.2 Million
762,200 Added 5954.69%
775,000 $56.6 Million
Q2 2021

Aug 16, 2021

SELL
$61.91 - $67.42 $17.8 Million - $19.4 Million
-287,200 Reduced 95.73%
12,800 $855,000
Q3 2020

Nov 16, 2020

BUY
$57.43 - $63.64 $5.74 Million - $6.36 Million
100,000 Added 50.0%
300,000 $18.1 Million
Q2 2020

Aug 14, 2020

SELL
$54.82 - $64.09 $45.1 Million - $52.7 Million
-822,500 Reduced 80.44%
200,000 $11.8 Million
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $37.3 Million - $40.7 Million
622,500 Added 155.63%
1,022,500 $62.7 Million
Q3 2017

Nov 14, 2017

BUY
$55.23 - $63.74 $22.1 Million - $25.5 Million
400,000
400,000 $25.5 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.